Dr. Matthew Davids on advances in CLL treatment | Dana-Farber Cancer Institute

Matthew Davids, MD, MMSc shares updates from the ASH 2017 Annual Meeting on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients. Learn more about Dana-Farber’s Center for Chronic Lymphocytic Leukemia. http://www.dana-farber.org/center-for-chronic-lymphocytic-leukemia/